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Abstract
Purpose—To examine the effect of topical ranibizumab on clinically stable corneal
neovascularization (NV).
Methods—This was a prospective, open-label, monocentric, uncontrolled, non-comparative
study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for
3 weeks with a follow-up of 16 weeks. The main corneal neovascularization outcome measures
were: neovascular area (NA), the area occupied by the corneal neovessels; vessel caliber (VC), the
mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea
area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear
Infirmary, Boston, MA, USA.
Results—Statistically significant decreases in NA (55.3%, P<0.001), which lasted through 16
weeks, and VC (59%, P<0.001), which continued to improve up to week 16, were observed after
treatment. No significant decrease was observed in IA (12.3%, P=0.49). There was no statistically
significant change in visual acuity or intraocular pressure. No adverse events ascribed to the
treatment were noted.
Conclusions—Topical application of ranibizumab is effective in reducing the severity of
corneal NV in the context of established corneal NV, mostly through decrease in VC rather than
IA.
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INTRODUCTION
Corneal neovascularization (NV) is a significant clinical problem1,2. In the United States it
is estimated that approximately 1.4 million patients suffer from corneal NV. Of these, 12%
are associated with a decrease in visual acuity. Moreover, corneal angiogenesis acts as a
strong risk factor for penetrating keratoplasty3. Indeed, survival rates for corneal grafts
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placed into vascularized recipient beds (so called ‘high-risk’ keratoplasty) often decrease to
below 50% even with local and systemic immune suppression4. In addition to its effects on
corneal immunoinflammatory responses, corneal NV can lead to corneal scarring, edema,
and lipid deposition and is associated with visual impairment and blindness worldwide.
Current treatments for corneal NV include pharmacological approaches such as
corticosteroids and non-steroidal anti-inflammatory agents – both of which may be
associated with serious side effects, such as ocular hypertension and corneal melting
respectively 1,5. Other treatments include laser photocoagulation, fine-needle diathermy and
photodynamic therapy6–11; however, vessel recanalization and stromal injury have been
associated with these approaches. Surgical approaches, aimed at restoration of the ocular
surface, including amniotic membrane-based transplantation, have also been described with
varying degrees of success1.
Members of the vascular endothelial growth factor (VEGF) family mediate angiogenesis,
and it has been shown that VEGF is up-regulated in inflamed and vascularized corneas in
both humans and animal models12. Clinically, VEGF inhibitors such as pegaptanib sodium
(Macugen™, OSI/Eyetech), ranibizumab (Lucentis™, Genentech) and off-label
bevacizumab (Avastin™, Genentech) are currently used for the treatment of various retinal
diseases such as neovascular age-related macular degeneration13,14. In addition, inhibition of
angiogenesis by neutralization of VEGF-A has been shown to promote corneal graft survival
in animal models15. Specifically, ranibizumab has been tested in animal models where it
was found to significantly reduce corneal neovascularization16,17.
Bevacizumab and ranibizumab have similar VEGF-binding characteristics because both
drugs are related to each other. Bevacizumab is a full-length, humanized monoclonal
antibody whereas ranibizumab is a humanized antibody fragment against VEGF-A18. Given
the encouraging results using bevacizumab for the treatment of corneal NV19 and the fact
that ranibizumab has a smaller molecular weight (48kD) than bevacizumab (149kD), we
tested the efficacy and safety of topical ranibizumab as a potential treatment modality for
corneal NV.
MATERIALS AND METHODS
This was an open label, single center uncontrolled, study investigating the safety and
efficacy of off-label topically administered ranibizumab in patients affected by corneal NV.
This study was approved by the Institutional Review Board of the Massachusetts Eye and
Ear Infirmary. Potential patients signed an informed consent at the time of the screening
visit.
Patients
Consecutive, eligible patients were identified for inclusion in the study. Adult patients of
either sex with clinically stable corneal NV were eligible for participation. Ten eyes of 9
patients (4 females and 5 males) were recruited. Stable corneal NV was defined with
inclusion and exclusion criteria as follows. Patients with superficial or deep corneal
neovessels extending more than 2 mm from the limbus were considered. Exclusion criteria
were: (a) current or recent (≤3 months) episode of corneal and ocular surface infection (of
whatever origin); (b) ocular surgery in study eye, including cataract surgery, keratoplasty,
ocular surface reconstruction, limbal stem cell transplantation or amniotic membrane
transplantation within 3 months prior to study entry; (c) current or recent (≤3 months) use of
contact lens; (d) current or recent (≤3 months) persistent corneal epithelial defects (of at
least 14 days in duration measuring more than 1 mm2); (e) recent (≤1 month) change in dose
and frequency of topical steroids and/or nonsteroidal anti-inflammatory agents; and (f)
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ocular or periocular neoplasias. Other non-ocular exclusion criteria were: uncontrolled
hypertension (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥90mmHg),
history of a thromboembolic event, coagulation abnormalities (including current
anticoagulant except aspirin) and diabetes mellitus.
Patients were consented for enrollment according to an institutional Human Studies
Committee-approved process and were treated with 1% (10mg/ml) topical ranibizumab 4
times a day for 3 weeks. This study was administered under an Investigational New Drug
application (IND 100,859) provided by the Food and Drug Administration.
Study medication
A topical ranibizumab solution was aseptically formulated by the Massachusetts Eye and
Ear Infirmary Clinical Pharmacy as follows: 2ml single-use vials were prepared using a 1%
(10 mg/ml) of preservative-free, single use ranibizumab aqueous solution containing 10 mM
histidine HCl, 10%, a-trehalose dihydrate, and 0.01% polysorbate 20 (pH 5.5). Each patient
received 84 single use dropper containers with instructions to use one single use dropper
container for each application and discard each dropper container after one use. Patients
were instructed to refrigerate the study drug at 2–8°C (36–46°F). In order to reduce the
chance of systemic absorption of ranibizumab, both puncta of the study eye were
temporarily plugged for the duration of treatment (3 weeks).
Study protocol
To determine the safety and efficacy of topical ranibizumab for the treatment of corneal NV,
follow-up visits were scheduled at weeks 1, 3, 8, and 16. Patients were instructed to strictly
follow the study visit schedule. At all visits a full ocular examination was completed,
including visual acuity (VA) measurements, corneal photographs, central corneal thickness
measured by ultrasound pachymetry and a detailed review of the general, medical and
pharmacological history. Adverse event monitoring was performed throughout the study.
Systolic and diastolic blood pressure measurements were obtained at all visits.
Main outcome measures
Safety—Safety was monitored via occurrence of adverse events (AEs). Both ocular and
systemic AEs were monitored during the study. Ocular adverse events were identified by
eye examination, VA testing, intraocular pressure, and ocular surface fluorescein staining up
to week 16. Systemic adverse events were identified by blood pressure measurements,
patient reporting, and physical examinations up to week 16. This study did not include blood
sampling or any pharmacokinetic measures.
Efficacy—We considered the extent of corneal NV, as measured by neovascular area,
vessel caliber, and invasion area, to be the primary efficacy variable. By comparing baseline
corneal photographs with follow-up photographs, as detailed below, the change in corneal
NV was evaluated. Secondary efficacy variables included measuring the changes in best-
corrected visual acuity and central corneal thickness from baseline to the last visit.
Three primary metrics for corneal NV (Fig. 1) were considered, as previously described15.
The following metrics were extrapolated from the digital pictures: Neovascular Area (NA),
the area of the corneal vessels themselves when projected into the plane of a photograph;
Vessel Caliber (VC), the mean diameter of the corneal vessels; Invasion Area (IA), the
fraction of corneal area in which vessels are present. Digital slit-lamp corneal pictures were
analyzed morphometrically using graphic editing software (Photoshop® CS2; Adobe
Systems Inc.) and a mathematical program (written using Matlab®; Mathworks Inc.).
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After the total corneal area was outlined, the blood vessels were enhanced and traced with
Photoshop tools and filters, then NV parameters were extrapolated as described elsewhere19.
Statistical analysis
To assess the difference in the three metrics, three different time points were considered: (1)
the screening visit, (2) the 3-week visit (end of treatment), and (3) the 16-week visit.
Repeated–measures ANOVA with complementary post-hoc Bonferroni test was performed
comparing cohort scores for each metric. In each case the hypothesis was a reduction in
cohort scores for a given metric from the earlier time point to the later time point. P≤0.05
was considered statistically significant.
RESULTS
Ten eyes of 9 patients (4 females and 5 males) were included in this study. The mean age of
the subjects was 57.3 (SD 14.5) and ranged from 30 to 78 years. Table 1 provides the
demographics of the study population. Patient medications at time of screening are described
in Table 2.
Neovascular Area
A statistically significant decrease in NA was found across the cohort (P<0.001). Post-hoc
Bonferroni test revealed a significant reduction from the screening visit to the 3-week visit
(P<0.05). The treated eyes also showed a significant reduction in the NA from the screening
visit to the 16-week visit (P<0.001) (Fig. 2 and 3). The mean change in the NA from the
initial to the 3-week visit was 39.8% (SD, 24.1%). The mean reduction in NA across the
cohort was 55.3% (SD, 44.4%) ranging from 27% to 99.6%. No significant change was
noticed from the 3-week visit to the 16-week visit (P=0.13) indicating sustained treatment
outcome up to week 16.
Vessel Caliber
A statistically significant decrease in VC was observed across the cohort (P<0.001). Post-
hoc Bonferroni test showed a significant reduction from the screening visit to the 16-week
visit (P<0.001) (Fig. 2). The mean change in the VC from the initial to the 3-week visit was
25.8% (SD, 18.8%). The mean reduction in VC across the cohort was 59% (SD, 34.9%)
ranging from 36.3% to 98.9%. There was a significant reduction in VC from the 3-week
visit to the 16-week visit (P<0.05) indicating continued improvement up to week 16.
Invasion Area
No significant change in the IA was observed across the cohort (P=0.26). The mean change
in IA was 31.6% (P= 0.87, SD, 67.4) and 12.3% (P=0.49, SD, 54.7) from the baseline visit
to the 3-week and the 16-week visits, respectively..
Other End-points and Adverse Events
Visual acuity—Conversion to logMAR equivalents of Snellen visual acuity was
performed for analysis of visual acuity changes. Mean corrected logMAR visual acuity (the
lower the logMAR score, the higher the degree of acuity) was 0.68 (SD, 0.62) at the
screening visit, 0.48 (SD, 0.43) at the 3-week visit, and 0.55 (SD, 0.37) at the last visit.
Changes in visual acuity from the baseline to any of the follow-up visits were not found to
be significant.
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Corneal thickness—Mean values for central corneal thickness were 632um (SD, 106um)
at baseline, 571um (SD, 109um) at 3 weeks, and 571um (SD, 45um) at 16 weeks; there were
no statistically significant differences between these time points.
Intraocular pressure—No significant change was found in intraocular pressure from
baseline to the 3-week visit and from baseline to the 16-week visit.
Systemic blood pressure—Mean arterial blood pressure (MAP) ([(2×diastolic blood
pressure) + systolic blood pressure]/3) at week 1, week 3, and week 16 were compared with
baseline visit measurements. The mean (±SD) of MAP for all patients was 90.6 (±12)
mmHg at the baseline, 89.8 (±7.1) mmHg at 1 week (P =0.85), 86.9 (±10.1) mmHg at 3
weeks (P=0.46), and 86.7 (±9.6) mmHg at 16 weeks (P =0.47). In summary, MAP did not
appear significantly affected by ranibizumab topical application.
No systemic or ocular adverse events including thromboembolic events, hemorrhage,
allergic reaction, ocular surface toxicity and epitheliopathy (superficial punctate
keratopathy, epithelial erosion or defect) or burning upon instillation were reported. Self-
reported compliance was extremely favorable; no patients reported to have missed doses of
the study drug throughout the entire treatment period.
DISCUSSION
Corneal NV represents a challenging clinical condition that may also lead to significant
visual impairment. Current therapies aiming to induce the regression of corneal vessels are
not uniformly effective and are variably associated with undesirable side-effects5,9. Several
VEGF inhibitors are currently used for the treatment of neovascular age-related macular
degeneration and macular edema20,21. Several studies have evaluated the application of
topical bevacizumab, at different concentrations,19,22–24 for treatment of corneal NV.
Concerns have been raised in regard to prolonged topical application of bevacizumab, as
VEGF may be a critical modulator of wound healing,25 and has also been implicated as a
nerve trophic factor 26. Indeed, the loss of epithelial integrity has been reported with topical
use of bevacizumab at 1.25% concentration when applied for prolonged periods (2
months)22. In light of these findings, although we did not observe the development of
epithelial defects in the course of our study with ranibizumab, we suggest caution should be
taken when treating patients with sub-optimal ocular surface integrity.
Ranibizumab, a Fab fragment related to bevacizumab, has been used to treat pterygia via
subconjunctival injection with no reported side effects27; prompt regression of microvessel
in the pterygium bed has been described28. Additionally, subconjunctival ranibizumab has
been shown effective in inhibiting neoplastic NV in ocular surface neoplasias29,30.
However, topical application of ranibizumab has not been reported to date in a clinical
setting.
In the aggregate, the existing literature suggests that local delivery of ranibizumab to the
anterior segment of the eye is not associated with significant side effects. Moreover, studies
from intravitreal administration of ranibizumab suggest that it is well tolerated and not
associated with clinically significant safety risks during and up to two years of treatment31.
However, no reports are available describing application of topical ranibizumab in corneal
NV. The current pilot study was performed to evaluate the efficacy of topical ranibizumab in
the treatment of corneal NV and to make comparisons with a similar treatment regimen for
topical bevacizumab (same concentration [10mg/ml], treatment frequency [4x daily] and
duration [3 weeks]) reported by our group19.
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In the current study, we found that topical ranibizumab 1% is effective in the treatment of
clinically stable corneal NV as evidenced by a significant reduction in two corneal NV
parameters (NA and VC). The average reduction in NA from baseline was 39.8% by week 3
and 55.3% by week 16, with no statistically significant difference between these two time
points indicating sustained treatment effect up to week 16. Interestingly, VC continued to
decrease significantly up to week 16, suggesting not only sustained, but potentially
progressive, treatment efficacy beyond treatment termination at week 3. The average
decrease in VC was 25.8% by week 3 and 59.0% by week 16. This progressive effect on VC
is in line with our observations with use of topical bevacizumab19. Given that patients
enrolled into this study, and our earlier trial with bevacizumab with stable NV, we do not
believe that this sustained efficacy beyond drug termination is simply a reflection of the
natural history of NV regression. This is in contrast with the well-known requirement for
repeat treatment in neovascular AMD and other proliferative retinopathies13,14,32. In our
study, the significant reduction of NA and VC in the absence of a significant change in IA
suggests that the main outcome of ranibizumab treatment is to induce narrowing of blood
vessels more than a reduction in their length. It is important to emphasize again that in this
study only patients with stable neovascularization were treated. Stable NV is less influenced
by VEGF blockade as opposed to newly formed vessels; this may explain the absence of
significant reduction in the NV invasion area.
Topical application of bevacizumab 1% for treatment of corneal NV has similarly been
studied by our group.19 In that study 10 patients with corneal NV were treated with 1%
topical bevacizumab for 3 weeks. Since our current study used the same efficacy parameters
to evaluate corneal NV, a comparison between these two studies can be made. For NA we
found a reduction of 55% (SD, 44%) with ranibizumab as opposed to 47% (SD, 37%) with
bevacizumab by week 16. VC was reduced by 59% (SD, 35%) with ranibizumab as opposed
to 54% (SD, 28%) after bevacizumab by week 16. No significant difference of IA was found
in either trial. Though not statistically significant, the decreases in NA and VC were
consistently greater for patients treated with ranibizumab at the comparable time points.
Thus, given the small sample sizes of these studies, we cannot derive definitive conclusions
regarding the relative efficacies of these two anti-VEGF-A agents. Indeed, this was an open-
label and non-comparative study and was designed as a pilot study to test the efficacy of
topical ranibizumab in patients with corneal NV.
Ranibizumab, designed for intraocular injection, has a relatively low (49kD) molecular
weight (MW) – approximately one third of the MW of bevacizumab. Thus, it is possible that
it could better penetrate the corneal epithelial barrier than larger MW biologic agents such as
bevacizumab33 and thus reaching higher therapeutic concentrations in the stroma. Clearly,
however, additional comparative efficacy studies are required before any conclusion can be
drawn regarding the apparent, modestly enhanced efficacy of topical ranibizumab as
compared to bevacizumab in the treatment of corneal NV.
Finally, as is increasingly true for any therapeutic strategy, the efficacy of the treatment
should be balanced against its costs. Thus, it is important to emphasize that there is a
significant cost difference between bevacizumab and ranibizumab. It is noteworthy that
clinical adoption of topical ranibizumab for treatment of corneal NV may be prohibitive due
to the current pricing of the drug.
In summary, this study provides novel evidence for the efficacy and safety of topical
ranibizumab in the treatment of corneal NV across a diverse spectrum of corneal
neovascular pathology. Further and larger studies are needed to better establish the efficacy
profile of this drug and optimize its dosing and formulation.
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Fig. 1.
Quantification of corneal neovascularization. Digital slit lamp corneal photographs were
analyzed using Photoshop CS2 and a mathematical program (Matlab, Mathworks Inc.). The
total area of the cornea was isolated and blood vessels were manually extracted using
Photoshop. To analyze the effect of ranibizumab three metrics were considered using a
Matlab script: Neovascular Area, measuring the area of the corneal vessels themselves;
Vessel Caliber, determining the mean diameter of the corneal vessels; and Invasion Area,
measuring the fraction of the corneal area in which the vessels are present.
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Fig. 2.
Summary of changes in response to ranibizumab topical therapy at the different time points
in the neovascular area, vessel caliber, and invasion area. The reduction in the neovascular
area and vessel caliber were statistically significant. There was no statistically significant
change in the invasion area.
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Fig. 3.
The effect of topical ranibizumab on patient number 5. Upper row: The screening picture
shows neovessels branching into the cornea from the 3 o’clock position. The vessels were
progressively reduced in caliber and in extension already 3 weeks after the initiation of the
treatment; the effect appeared to continue up to week 16. Lower row: corneal neovessels
extracted from the corresponding pictures.
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TABLE 1
Study population characteristics.
Patient Eye Gender Age at enrollment Diagnosis at enrollment
1 OS F 78 Corneal NV; s/p band keratopathy LID 11/20/07
2* OD M 57 Corneal NV OU; h/o perforated Pseudomonas corneal ulcer, s/p patch graft LID 12/26/07
2* OS M 57 Corneal NV OU; s/p lamellar excision of corneal scar, amniotic membrane transplantation
LID 12/26/07
3 OS F 52 H/o HZV keratitis; neurotrophic keratopathy, lipid keratopathy LID 04/07
4 OS M 65 s/p chemical burn OU; limbal stem cell deficiency OS LID 06/10/08
5 OD M 70 s/p excision of primary pterygium with conjunctival autograft and amniotic membrane
LID 10/22/08
6 OD F 69 HSV Keratitis, central corneal scar LID 1985
7 OS F 30 HSV Keratitis, central corneal scar LID 2/18/08
8 OD M 39 HZV Keratitis LID 01/08
9 OD M 56 s/p LASIK; s/p PK for Pseudomonas corneal ulcer LID 03/11/09
NV: neovascularization; s/p: status post; LID: last inflammation clinically detected; HZV: herpes zoster keratitis; HSV: herpes simplex keratitis.
*
Both eyes of Patient 2 were analyzed in this study.
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TABLE 2
Current medications at time of enrollment. Oral medications are shown in parentheses.
Subject number Meds at screening visit
1 Erythromycin 0.5% OD
Artificial tears
Prednisolone acetate 1% TID OS
2 (OD) Prednisolone acetate 1% BID OS
Medroxyprogesterone 1% QID OS
Artificial tears OD
Erythromycin 0.5% TID OS
(Doxycycline 100mg QD)
2 (OS) Prednisolone acetate 1% BID OS
Medroxyprogesterone 1% QID OS
Artificial tears OD
Erythromycin 0.5% OS
(Doxycycline 100mg QD)
3 Prednisolone acetate 1% QD OS
4 Bacitracin OU
(Doxycycline 100mg QD)
5 Prednisolone Acetate 1% BID OD
6 Artificial tears
(Acyclovir 400mg BID)
7 Artificial tears
(Acyclovir 400mg BID)
8 Artificial tears
9 Prednisolone acetate 1% TID OD
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